Vineet Laboratories Limited
: VINEETLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vineet Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vineet Laboratories Ltd is an Indian pharmaceutical company engaged in the design, development, and manufacturing of API intermediates and bulk drugs. The company also operates in the chemicals and pesticides sectors, while maintaining R&D capabilities across biotechnology and healthcare.
Business Model
The company generates revenue through the manufacturing and distribution of pharmaceutical products, bulk drugs, and chemical formulations. It further leverages its R&D infrastructure to facilitate the import and export of specialised chemical products.
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its chemical formulation portfolio and leveraging its R&D capabilities in the biotechnology and industrial sectors.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards that may impact operational continuity if not met.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and bulk drug inputs can significantly affect profit margins.
- Export Market Dependency. As an exporter of chemical formulations, the company is exposed to geopolitical risks and changes in international trade policies.
- R&D Execution Risk. The failure to successfully commercialise new pharmaceutical or chemical formulations could hinder long-term growth prospects.
Start your research today
Unlock AI insights, financials, peers and live data on Vineet Laboratories Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vineet Laboratories LimitedVINEETLAB | ₹74 Cr | — | — | — | -22.0% | — | — | +14.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2025
Financials
Vineet Laboratories Limited
: VINEETLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vineet Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vineet Laboratories Ltd is an Indian pharmaceutical company engaged in the design, development, and manufacturing of API intermediates and bulk drugs. The company also operates in the chemicals and pesticides sectors, while maintaining R&D capabilities across biotechnology and healthcare.
Business Model
The company generates revenue through the manufacturing and distribution of pharmaceutical products, bulk drugs, and chemical formulations. It further leverages its R&D infrastructure to facilitate the import and export of specialised chemical products.
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its chemical formulation portfolio and leveraging its R&D capabilities in the biotechnology and industrial sectors.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards that may impact operational continuity if not met.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and bulk drug inputs can significantly affect profit margins.
- Export Market Dependency. As an exporter of chemical formulations, the company is exposed to geopolitical risks and changes in international trade policies.
- R&D Execution Risk. The failure to successfully commercialise new pharmaceutical or chemical formulations could hinder long-term growth prospects.
Start your research today
Unlock AI insights, financials, peers and live data on Vineet Laboratories Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2025